as 11-06-2025 3:54pm EST
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
Upcoming Earnings Alert:
Get ready for potential market movements as Kodiak Sciences Inc KOD prepares to release earnings report on 13 Nov 2025.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 795.5M | IPO Year: | 2018 |
| Target Price: | $19.29 | AVG Volume (30 days): | 964.2K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.92 - $21.17 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
KOD Breaking Stock News: Dive into KOD Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Simply Wall St.
a month ago
PR Newswire
4 months ago
GlobeNewswire
4 months ago
Zacks
5 months ago
Simply Wall St.
5 months ago
PR Newswire
5 months ago
Zacks
6 months ago
The information presented on this page, "KOD Kodiak Sciences Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.